ASX ANNOUNCEMENT 24 September 2020
Further Data Confirms Potential Utility of Cymerus MSCs in Restoring Cardiac Function Following Heart Attack
Melbourne, Australia; 24 September 2020:
Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce further positive efficacydata from a study of its Cymerus™ mesenchymal stem cells (MSCs) in a preclinical heart attack model.
Inparticular, treatment with Cymerus MSCs was shown to enhance the recovery of the blood supply to the damaged heart through the generation of new blood vessels. New vessel formation is accepted as an essential element of repair after the damage caused by a myocardial infarction, i.e. heart attack.Key Highlights
• Additional efficacy data from preclinical disease model on recovery of cardiac function post heart attack help to explain the previously announced superior therapeutic effects demonstrated by Cymerus MSC treatment when compared to conventional bone marrow derived MSC treatment and placebo
• The new data show that Cynata’s Cymerus MSCs enhance the recovery of the blood supply to the damaged heart by:- Enhancing the development of new blood capillaries (around twice as many capillaries were shown in the Cymerus MSC group versus placebo controls)-
Enhancing arteriogenesis (growth of arterioles: small blood vessels) - whereas bone marrow derived MSCs did not (nearly three times as many arterioles were shown in the Cymerus MSC group versus placebo controls)- Releasing higher levels of molecules known to be involved in the stimulation of new bloodvessel growth (provides a rationale for the increased growth of blood vessels seen followingtreatment with Cymerus MSCs)• This builds on the significant dataset demonstrating the potential benefits of treatment with Cynata’s Cymerus MSCs and Cynata will continue to work with relevant parties to determine the next steps for this program and broader clinical development The data arise from further studies conducted by a team led by Associate Professor James Chong(Westmead Institute for Medical Research, Sydney).
As previously announced, initial studies by Associate Professor Chong’s team showed that Cymerus MSC treatment improved recovery of cardiac function post heart attack compared to either placebo or bone marrow-derived MSCs (BM-MSCs).
The latest results help to explain the mechanism for the superior therapeutic effects of Cymerus MSCs compared to conventional BM-MSCs and placebo in this disease model. The data from this study will be submitted for publication to a peer-reviewed medical journal.Dr Kilian Kelly, Cynata’s Chief Operating Officer, said: “With the benefit of this further data we are now able to better understand the beneficial effects of our Cymerus MSCs in this model of heart attack.
It is particularly notable that the latest results are consistent with the greater benefit demonstrated byCymerus MSCs over BM-MSCs in the earlier studies of heart function. Given the scalability and consistency advantages of the Cymerus MSC manufacturing process over conventional processes, the potential therapeutic advantages shown here are particularly interesting as a putative treatment for post heartattack cardiac damage.”-ENDS Authorised for release by Dr Ross Macdonald, Managing Director & CEO
BEST CELLS IN THE WORLD.
(20min delay)
